Advances in the Management of Pediatric Asthma: A Review of Recent FDA Drug Approvals and Label Updates

References

• National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics—2002.J Allergy Clin Immunol 2002; 110(5 suppl):S141–S219. [CSA]
   Google Scholar
• National Center for Health Statistics. Fast Stats: Asthma, 2003. http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed October 20, 2003.
   Google Scholar
• Hing E, Middleton K. National Hospital Ambulatory Medical Care Survey: 2001 outpatient department summary.Adv Data 2003; 338:1–26. [CSA]
   Google Scholar
• Environmental Protection Agency. Asthma Facts. 2004, EPA 402-F-04-019.
   Google Scholar
• McCaig L F, Burt C W. National Hospital Ambulatory Medical Care Survey: 2002 emergency department summary.Adv Data 2004; 340):1–34. [CSA]
   PubMedGoogle Scholar
• National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2000–2001. 2001. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm. Accessed April 1, 2003. [CSA]
   Google Scholar
• Uses of drugs not described in the package insert (off-label uses).Pediatrics 2002; 110(1 Pt 1):181–183. [CSA], [CROSSREF]
   Google Scholar
• One Hundred Seventh Congress of the United States of America. Best Pharmaceuticals for Children Act. Washington, D.C.: Government Printing Office, 2001:S.1789-1–S.1789-17.
   Google Scholar
• Roberts R. The federal government: recent changes at FDA and the implications for pediatric clinical trials. 2002:1–45. [CSA]
   Google Scholar
• National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NIH Publication No. 97-4051, 1997:1–152.
   Google Scholar
• American Academy of Allergy Asthma and Immunology. Pediatric asthma: promoting best practice: guide for managing asthma in children.Am Acad Pediatr 1999:1–157. [CSA]
   Google Scholar
• Spahn J D, Szefler S J. Childhood asthma: new insights into management.J Allergy Clin Immunol 2002; 109(1):3–13. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Vanden Burgt J A, Busse W W, Martin R J, Szefler S J, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma.J Allergy Clin Immunol 2000; 106(6):1209–1226. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Advair Diskus® Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline, 2004:RL-2128.
   Google Scholar
• Wildhaber J H. Nebuliser therapy in children. In: Business Briefing: Global Healthcare 2003. 5th ed. London: World Medical Association, Business Briefings Ltd., 2003:91–93.
   Google Scholar
• Food and Drug Administration. CDER 2003 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, MD: FDA, 2004.
   Google Scholar
• Skoner D P, Szefler S J, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith J A. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma.J Allergy Clin Immunol 2000; 105(2 Pt 1):259–268. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Szefler S J, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma.J Allergy Clin Immunol 2002; 109(4):730–742. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kemp J P, Skoner D P, Szefler S J, Walton-Bowen K, Cruz-Rivera M, Smith J A. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children.Ann Allergy Asthma Immun 1999; 83(3):231–239. [CSA]
   PubMed Web of Science ®Google Scholar
• Shapiro G, Mendelson L, Kraemer M J, Cruz-Rivera M, Walton-Bowen K, Smith J A. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma.J Allergy Clin Immunol 1998; 102(5):789–796. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baker J W, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants.Pediatrics 1999; 103(2):414–421. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Scott M B, Ellis M H, Cruz-Rivera M, Fitzpatrick S, Smith J A. Once-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthma.Ann Allergy Asthma Immun 2001; 87(6):488–495. [CSA]
   Google Scholar
• Leflein J G, Szefler S J, Murphy K R, Fitzpatrick S, Cruz-Rivera M, Miller C J, Smith J A. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial.Pediatrics 2002:866–872. [CSA], [CROSSREF]
   Google Scholar
• Forest Pharmaceuticals. I. Aerobid Package Insert. 2002.
   Google Scholar
• Food and Drug Administration. Aerobid Black Box Letter (Supplemental NDA). Forest Pharmaceuticals, Inc., 2003. http://www.fda.gov/cder/foi/appletter/2003/18340slr021ltr.pdf. Accessed September 22, 2004.
   Google Scholar
• Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated.Expert Opin Pharmacother 2004; 5(5):1163–1173. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Approves Foradil Aerolizer (Formoterol Fumarate Inhalation Powder). Rockville, MD: FDA, 2002:1–4, Report no. 20-831.
   Google Scholar
• Foradil® Aerolizer™ (formoterol fumarate inhalation powder). In: Physicians' Desk Reference. 57 ed. Montvale, NJ: Thomson PDR, 2003:2275–2278.
   Google Scholar
• Pearlman D S, Kottakis J, Till D, Della C G. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children.Curr Med Res Opin 2002; 18(8):445–455. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bensch G, Berger W E, Blokhin B M, Socolovsky A L, Thomson M H, Till M D, Castellsague J, Della C G. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.Ann Allergy Asthma Immun 2002; 89(2):180–190. [CSA]
   Google Scholar
• Bisgaard H. Long-acting β2-agonists in management of childhood asthma: a critical review of the literature.Pediatr Pulmonol 2000; 29(3):221–234. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jones S L, Cowan J O, Flannery E M, Hancox R J, Herbison G P, Taylor D R. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.Eur Respir J 2001; 17(3):368–373. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Lipworth B J, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration.Chest 2000; 117(1):156–162. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Talk Paper: Study of Asthma Drug-Halted. Rockville, MD: FDA, 2003:T03–T06.
   Google Scholar
• US Food and Drug Administration. Labeling Changes for Drug Products That Contain Salmeterol. Washington, DC: FDA, 2003:1–2, T03-62..
   Google Scholar
• Wooltorton E. Salmeterol (Serevent) asthma trial halted early.CMAJ 2003; 168(6):738. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Rickard K A. GlaxoSmithKline. Prescriber of Serevent. Healthcare Professional, 2003.
   Google Scholar
• Garcia-Marcos L, Schuster A, Cobos B N. Inhaled corticosteroids plus long-acting β2-agonists as a combined therapy in asthma.Expert Opin Pharmacother 2003; 4(1):23–39. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M. CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4.J Allergy Clin Immunol 2003; 111(5):1032–1040. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Bisgaard H. Leukotriene modifiers in pediatric asthma management.Pediatrics 2001; 107(2):381–390. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Chowdhury B A. Department of Health and Human Services. NDA 21-409/S-003: Singulair (Montelukast Sodium) Oral Granuals; Application Approval. Hanlon, W. A. and Merck Research Laboratories, 2002.
   Google Scholar
• Merck and Co. Inc. Singulair (Montelukast Sodium) Tablets, Chewable Tablets, and Oral Granules. Whitehouse Station, NJ: Merck and Co. Inc., 2002:1–15, 9088815.
   Google Scholar
• Dubus J C, Anhoj J. A review of once-daily delivery of anti-asthmatic drugs in children.Pediatr Allergy Immunol 2003; 14(1):4–9. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Knorr B, Franchi L M, Bisgaard H, Vermeulen J H, LeSouef P, Santanello N, Michele T M, Reiss T F, Nguyen H H, Bratton D L. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.Pediatrics 2001; 108(3):1–10. [CSA], [CROSSREF]
   Google Scholar
• Melo R E, Sole D, Naspitz C K. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses.J Allergy Clin Immunol 2003; 111(2):301–307. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Vidal C, Fernandez-Ovide E, Pineiro J, Nunez R, Gonzalez-Quintela A. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction.Ann Allergy Asthma Immun 2001; 86(6):655–658. [CSA]
   Google Scholar
• US Food and Drug Administration. Summary of Safety-Related Drug Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER) April 2001, 2001. http://www.fda.gov/medwatch/safety/2001/apr01.htm. Accessed March 26, 2003.
   Google Scholar
• Pearlman D S, Lampl K L, Dowling P J Jr, Miller C J, Bonuccelli C M. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.Clin Ther 2000; 22(6):732–747. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• McMillan R M. Leukotrienes in respiratory disease.Paediatr Respir Rev 2001; 2(3):238–244. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Carl J C, Kercsmar C M. Management of acute pediatric asthma.Curr Allergy Asthma Rep 2002; 2(6):468–476. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Strunk R C, Nicklas R A, Milgrom H, Ikle D. Fatal and near-fatal asthma questionnaire: prelude to a national registry.J Allergy Clin Immunol 1999; 104(4 Pt 1):763–768. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Penn R B, Frielle T, McCullough J R, Aberg G, Benovic J L. Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2-adrenergic receptors.Clin Rev Allergy Immunol 1996; 14(1):37–45. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baramki D, Koester J, Anderson A J, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer.J Allergy Clin Immunol 2002; 109(3):449–454. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Templeton A G, Chapman I D, Chilvers E R, Morley J, Handley D A. Effects of S-salbutamol on human isolated bronchus.Pulm Pharmacol Ther 1998; 11(1):1–6. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Cho S H, Hartleroad J Y, Oh C K. (S)-albuterol increases the production of histamine and IL-4 in mast cells.Int Arch Allergy Immunol 2001; 124(4):478–484. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mitra S, Ugur M, Ugur O, Goodman H M, McCullough J R, Yamaguchi H. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle.Mol Pharmacol 1998; 53(3):347–354. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Milgrom H, Skoner D P, Bensch G, Kim K T, Claus R, Baumgartner R A. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol.J Allergy Clin Immunol 2001; 108(6):938–945. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Nelson H S, Bensch G, Pleskow W W, DiSantostefano R, DeGraw S, Reasner D S, Rollins T E, Rubin P D. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.J Allergy Clin Immunol 1998; 102(6 Pt 1):943–952. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Gawchik S M, Saccar C L, Noonan M, Reasner D S, DeGraw S S. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.J Allergy Clin Immunol 1999; 103(4):615–621. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Carl J C, Myers T R, Kirchner H L, Kercsmar C M. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.J Pediatr 2003; 143(6):731–736. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. FDA Acts to Make Drugs Safer for Children. Washington, DC: FDA, 2003, Report no. P98-37.
   Google Scholar
• Accolate® Zafirlukast tablets. In: Physicians' Desk Reference. 57 ed. Montvale, NJ: Thomson PDR, 2003:651–653.
   Google Scholar